(Reuters) - 2seventy bio will discontinue enrolling patients in a late-stage study of its cell-therapy Abecma, developed in partnership with Bristol-Myers Squibb, for treating patients with newly ...
On Wednesday, 2Seventy Bio Inc (TSVT) stock saw a decline, ending the day at $4.32 which represents a decrease of $-0.45 or -9.43% from the prior close of $4.77. The stock opened at $4.32 and touched ...
2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma. 2seventy on ...
Seventy Bio Inc (TSVT) stock saw a modest uptick, ending the day at $5.05 which represents a slight increase of $0.18 or 3.70% from the prior close of $4.87. The stock opened at $4.79 and touched a ...
Some results have been hidden because they may be inaccessible to you